{"id":"W2949444368","doi":"10.1097/01.hs9.0000561592.51072.9b","title":"S828 A RANDOMIZED, DOUBLE BLIND PHASE 2 STUDY OF 3 DIFFERENT DOSES OF PRM‐151 IN PATIENTS WITH MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH OR INELIGIBLE FOR RUXOLITINIB","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Essential thrombocythemia; Internal medicine; Randomization; Bone marrow; Polycythemia vera; Gastroenterology; Randomized controlled trial; Anemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003262399,0.0003480242,0.001875941,0.0001830472,0.00002938079,0.00001823844,0.0001620446,0.0001093708,0.002144212],"category_scores_gemma":[0.00005312975,0.0001887545,0.0001489089,0.000515019,0.0001296993,0.0000983771,0.00005395352,0.0001900488,0.000004367864],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009242212,"about_ca_system_score_gemma":0.0001928899,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000461836,"about_ca_topic_score_gemma":0.0004234751,"domain_scores_codex":[0.997447,0.0001348613,0.0007398194,0.0004780975,0.0007359572,0.0004642553],"domain_scores_gemma":[0.9980065,0.0003744833,0.0003316171,0.0006615399,0.0004655835,0.0001603048],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6907316,0.007296328,0.2959671,0.00126226,0.0004859821,0.000006857167,0.001557955,0.00001096551,0.001171189,0.00001568151,0.00008123071,0.001412789],"study_design_scores_gemma":[0.9385372,0.0264626,0.008935053,0.001801359,0.0004030833,0.000003967467,0.001877579,0.0001134745,0.02150937,0.000008870486,0.00009706875,0.0002503114],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818859,0.0001348473,0.00001212474,0.00002900996,0.00001924775,0.0164554,0.00003337286,0.0000291751,0.00140094],"genre_scores_gemma":[0.9888384,0.00004120067,0.0001658864,0.00001355525,0.00002839925,0.00089735,0.00008452416,0.00008081189,0.009849867],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.287032,"threshold_uncertainty_score":0.998768,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03123546288346078,"score_gpt":0.3296657506900283,"score_spread":0.2984302878065675,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}